No Prescription |
 |
 | ||
|
DACARB Generic Dacarbazine |
|
| ||
No Prescription » Prescription Drugs 5 » DACARB Generic Dacarbazine Dacarbazine is an anticancer (cytotoxic) medicine.Cancers form when some cells within the body multiply uncontrollably and abnormally. There are two types of cancer. Solid cancers where a lump forms e.g. the bone muscle brain cells etc. divide and multiply abnormally. The second type are leukaemias and lymphomas where the blood cells divide and multiply abnormally.Other characteristics of cancer besides uncontrolled growth include the ability of these abnormal cells to invade other tissues next to them or to break away from the original site travel through the blood or lymph and establish a new cancer at a different site of the body. These are called metastases.Like normal healthy cells cancer cells go through a continuous process of change. Each cell divides into two daughter cells. These cells grow rest and then divide again. The medicines used in chemotherapy are powerful chemicals designed to interupt this cycle and stop cells from growing.Several different types of anticancer medicines are used in chemotherapy. Each type kills cells at a different stage of the cell's life cycle. Each does its job in a different way.Dacarbazine is a synthetic compound. It works by blocking the production of genetic material (DNA) in the cell by binding it together. This prevents the cell from growing and therefore it dies.Unfortunately anticancer medicines will also affect the growth and division of normal healthy cells in the same way such as blood gut and hair cells. This can therefore cause several of the side effects seen with chemotherapy e.g. hair loss. The body's immune system also becomes suppressed increasing the risk of infections.In most chemotherapy regimens doses are administered in courses at various intervals to allow normal cells to recover from the adverse effects of the anticancer medicines between doses. However during this period cancer cells will also recover and start to replicate again. Successful treatment depends on the administration of the next course of therapy before the cancer has regrown to its previous size and the net effect is to decrease the amount of cancer with each successive course.Dacarbazine is used in combination with other anticancer medicines. It is administered by intravenous infusion.What is it used for?Breast cancer Cancer of the colon (large bowel) Cancer of the ovaries Cancer of the soft tissue e.g. muscle (soft tissue sarcoma)Lung cancer Lymph node cancer (Hodgkin's disease) Metastatic cancerous melanoma Testicular cancer Buy DACARB Generic Dacarbazine and other Prescription Drugs 5 products online at Medstore. 4812
About DACARB Generic Dacarbazine: Product Type: Prescription Drugs 5 DACARB ( Generic Dacarbazine ) DACARB (Generic Dacarbazine) Generic Dacarbazine 200MG 16 Tablets Generic Dacarbazine DACARB
View more Prescription Drugs 5 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
